<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Polcz M</submitter><funding>NCI NIH HHS</funding><pagination>2795-2803</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10184500</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Approximately 35% of patients with midgut neuroendocrine tumors (MNET) present with distant metastases. Although successful resection of these metastatic foci improves overall survival (OS), the role of primary tumor resection (PTR) in patients with unresectable metastatic disease is unclear. The aim of this study is to evaluate prevalence and survival impact of PTR in patients with unresectable metastatic MNET.&lt;h4>Patients and methods&lt;/h4>A retrospective cohort study of patients with metastatic MNET was performed using the National Cancer Database (2004-2014). Demographic and clinicopathologic variables were compared between patients who did and did not undergo PTR. Survival analysis was performed using Kaplan-Meier and log-rank tests. Multivariable regression analysis </pubmed_abstract><journal>Annals of surgical oncology</journal><pubmed_title>Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.</pubmed_title><pmcid>PMC10184500</pmcid><funding_grant_id>K12 CA090625</funding_grant_id><pubmed_authors>Kiernan C</pubmed_authors><pubmed_authors>Tan M</pubmed_authors><pubmed_authors>Schlegel C</pubmed_authors><pubmed_authors>Edwards GC</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Solorzano CC</pubmed_authors><pubmed_authors>Parikh A</pubmed_authors><pubmed_authors>Idrees K</pubmed_authors><pubmed_authors>Bailey CE</pubmed_authors><pubmed_authors>Polcz M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.</name><description>&lt;h4>Background&lt;/h4>Approximately 35% of patients with midgut neuroendocrine tumors (MNET) present with distant metastases. Although successful resection of these metastatic foci improves overall survival (OS), the role of primary tumor resection (PTR) in patients with unresectable metastatic disease is unclear. The aim of this study is to evaluate prevalence and survival impact of PTR in patients with unresectable metastatic MNET.&lt;h4>Patients and methods&lt;/h4>A retrospective cohort study of patients with metastatic MNET was performed using the National Cancer Database (2004-2014). Demographic and clinicopathologic variables were compared between patients who did and did not undergo PTR. Survival analysis was performed using Kaplan-Meier and log-rank tests. Multivariable regression analysis </description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Aug</publication><modification>2025-04-05T10:55:20.757Z</modification><creation>2025-04-05T10:55:20.757Z</creation></dates><accession>S-EPMC10184500</accession><cross_references><pubmed>32430752</pubmed><doi>10.1245/s10434-020-08602-7</doi></cross_references></HashMap>